RE:Big PictureLooked like a full on biotech slaughter today. Concordia seemed to take it worse than anybody. This can't all be because of Hillary's stupid tweet I'd hope. Interesting that retail investors can now get into Aralez for roughly the same price as Deerfield. Also interesting to see that the market now values POZEN at roughly the same price as it did before the merger and relocation was announced, which should tell you something about the volatility of market sentiment. Sucks yeah, but remember it's on no news and sector wide, so there's nothing really anyone can do. If the stock is still in the dumps by the end of 2016 (After the merger, after Yosprala etc) then I'll consider taking another look. Wondering if we'll see a burst of M&A in the next little while - pharma companies have deep pockets and valuations are looking cheap across the board. I still think TRX is ripe for a competing offer .....